Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
出版年份 2014 全文链接
标题
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
作者
关键词
-
出版物
EUROPEAN HEART JOURNAL
Volume 36, Issue 1, Pages 39-50
出版商
Oxford University Press (OUP)
发表日期
2014-08-21
DOI
10.1093/eurheartj/ehu319
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Journey Through Cholesteryl Ester Transfer Protein Inhibition
- (2013) Ioannis Karalis et al.
- Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
- (2013) Peter Libby NEW ENGLAND JOURNAL OF MEDICINE
- Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
- (2013) Susan Kühnast et al. PLoS One
- Cholesterol Efflux and Atheroprotection
- (2012) Robert S. Rosenson et al. CIRCULATION
- On- and Off-Target Pharmacology of Torcetrapib
- (2012) Douglas G. Johns et al. DRUGS
- Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
- (2012) Philip J. Barter et al. JOURNAL OF LIPID RESEARCH
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
- (2012) Benjamin F Voight et al. LANCET
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction
- (2011) D E Gutstein et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
- (2011) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin
- (2011) Susan Kühnast et al. JOURNAL OF HYPERTENSION
- Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
- (2011) Ronald M. Krauss et al. JOURNAL OF LIPID RESEARCH
- Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
- (2010) Laurent Yvan-Charvet et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
- (2008) Daniel Bloomfield et al. AMERICAN HEART JOURNAL
- Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
- (2008) José W.A. van der Hoorn et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity
- (2008) Menno Vergeer et al. CIRCULATION
- Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin
- (2008) Willeke de Haan et al. CIRCULATION
- Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
- (2008) R Krishna et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice
- (2007) Willeke de Haan et al. ATHEROSCLEROSIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started